MicroRNA Fingerprints During Human Megakaryocytopoiesis
AssigneeThe Ohio State University Research Foundation
InventorsCarlo M. Croce, Ramiro Garzon, George A. Calin
Life of this patent
Estimating the term…
Abstract
Described herein is a pharmaceutical composition for treating a subject having a cancer and/or myeloproliferative disorder associated with overexpression of a HOXA1 gene product where an effective amount of at least one miR-10a gene product or an isolated variant or biologically-active fragment thereof is administered to the subject sufficient to decrease expression of the HOXA1 gene product in the subject.
Claims17
A pharmaceutical composition for treating a subject exhibiting a cancer and/or a myeloproliferative disorder associated with overexpression of a transcription factor gene product from the homeobox gene family (HOXA1), wherein the cancer and/or myeloproliferative disorder is selected from the group consisting of:
- acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AMKL), multiple myeloma (MM), and chronic myelogenous leukemia (CML), the composition comprising an effective amount of at least one miR-10a gene product and a pharmaceutically-acceptable carrier, wherein the at least one miR-10a gene product binds to, and decreases expression of, the HOXA1 gene product in the subject.
An artificial agonist of miR-10a, wherein the agonist is a polynucleotide comprising a pri-miRNA, pre-miRNA, or mature sequence of miR-10a, and wherein administration of the agonist decreases expression of a HOXA1 gene product in at least one cell following administration of the agonist.
Dependencies are inferred from the claim text.